Boston Scientific (NYSE: BSX) revenue
Boston Scientific reported revenue of $20,074m for fiscal 2025, 19.9% more than in fiscal 2024 ($16,747m). Since fiscal 2016 its revenue has grown by 139.4%, an average growth of 10.2% a year.
Revenue by fiscal year
| Fiscal year | Revenue | Change | Operating profit | Operating margin |
|---|---|---|---|---|
| 2025 | $20,074m | +19.9% | $3,613m | 18.0% |
| 2024 | $16,747m | +17.6% | $2,603m | 15.5% |
| 2023 | $14,240m | +12.3% | $2,343m | 16.5% |
| 2022 | $12,682m | +6.7% | $1,649m | 13.0% |
| 2021 | $11,888m | +19.9% | $1,199m | 10.1% |
| 2020 | $9,913m | −7.7% | −$80.0m | −0.8% |
| 2019 | $10,735m | +9.3% | $1,518m | 14.1% |
| 2018 | $9,823m | +8.6% | $1,506m | 15.3% |
| 2017 | $9,048m | +7.9% | $1,285m | 14.2% |
| 2016 | $8,386m | — | $447.0m | 5.3% |
The change compares each fiscal year with the one before. Operating margin is operating profit over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Questions about the revenue of Boston Scientific
- How much revenue did Boston Scientific make in fiscal 2025?
- Boston Scientific reported revenue of $20,074m for fiscal 2025, compared with $16,747m in fiscal 2024.
- How much has the revenue of Boston Scientific grown?
- Between fiscal 2016 and fiscal 2025 it went from $8,386m to $20,074m: 139.4% more, an average growth of 10.2% a year.
- What was the best year for revenue at Boston Scientific?
- Of its last 10 fiscal years, fiscal 2025, with $20,074m.
- Where do the figures for Boston Scientific come from?
- From the annual report (Form 10-K) that Boston Scientific files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Boston Scientific files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019 · 2018 · 2017 · 2016. More on Boston Scientific: the Boston Scientific page · annual accounts · net income · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.